CA: Administration Core
CA:管理核心
基本信息
- 批准号:7507325
- 负责人:
- 金额:$ 14.51万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2008
- 资助国家:美国
- 起止时间:2008-07-01 至 2013-06-30
- 项目状态:已结题
- 来源:
- 关键词:Administrative CoordinationAdministratorAdvisory CommitteesApplications GrantsBusinessesCA-15-3 AntigenCancer CenterCenter Core GrantsChargeClinicalClinical Nursing ResearchClinical ResearchClinical TrialsCollaborationsCommunicationDataDevelopmentEducational ActivitiesEducational workshopEnsureEventFGFR3 geneFosteringFundingFutureGrantGuidelinesIndividualInstitutionIntellectual PropertyIntranetJointsLaboratory FindingLaboratory StudyLeadershipLicensingMonitorMultiple MyelomaNamesNodalOperative Surgical ProceduresPrincipal InvestigatorProgram DevelopmentProgress ReportsPublicationsPurposeReport (account)ReportingReproduction sporesResearchResearch InfrastructureResearch PersonnelResourcesRightsSamplingSecureSignal TransductionSiteSpecialistStructureSurvivorsTechnologyTechnology TransferTranslationsTravelWorkbench to bedsidecareercomplement resourcecostdayexperiencemembernovelpreclinical studyprogramsstemtrafficking
项目摘要
The purpose of the Administration, Communication, and Planning Core is to assure the coordination of
the Dana Farber/Harvard Cancer Center (DF/HCC) Myeloma SPORE components and to provide oversight
and leadership of the scientific, administrative, and fiscal aspects of the SPORE. The SPORE Director will
oversee the administrative coordination of the various clinical and laboratory studies outlined in this Program.
He will integrate scientific and clinical efforts within and between Projects, and assure the translation of
laboratory findings to the bedside; and conversely, the initiation of laboratory studies stemming from clinical
observations.
During the prior funding period, the infrastructure has been created to have seemless communication
and exchange of data between SPORE sites, facilitating collaborative preclinical studies and clinical trials.
Multiple joint publications, completed and ongoing clinical trials, and the translation of several novel targeted
therapies from bench to bedside confirm the communication and integration of our efforts. This Core will
continue to facilitate exchange of information among the SPORE members, as well as the internal and
external advisory committees. It will provide clinical research nursing support for the proposed clinical trials.
In addition, as in the previous funding period, a clinical study coordinator will assure appropriate sample
acquisition and trafficking. The grants administrator will allocate resources in a timely and integrated fashion
to facilitate successful completion of the proposed studies. The Specific Aims of the Administration,
Communication, and Planning Core are to:
1. Monitor research progress and plan for the future;
i
2. Foster collaborative research within the SPORE and between SPOREs;
3. Integrate the Myeloma SPORE into the DF/HCC structure;
4. Provide necessary resources and fiscal oversight; and
5. Promote rapid dissemination of significant research finding
政府,沟通和规划核心的目的是确保协调
Dana Farber/Harvard Cancer Center(DF/HCC)骨髓孢子成分并提供监督
以及孢子科学,行政和财政方面的领导。孢子导演将
监督该计划中概述的各种临床和实验室研究的行政协调。
他将在项目之间和项目之间整合科学和临床工作,并确保翻译
床边的实验室发现;相反,由临床研究引起的实验室研究的启动
观察。
在以前的资金期间,基础架构已被创建为具有毫无沟通的沟通
以及孢子站点之间的数据交换,促进了协作临床前研究和临床试验。
多个联合出版物,已完成和正在进行的临床试验以及几种针对性的新颖的翻译
从长凳到床边的疗法证实了我们努力的交流和整合。这个核心将
继续促进孢子成员以及内部和内部和
外部咨询委员会。它将为拟议的临床试验提供临床研究护理支持。
此外,与上一个资金期一样,临床研究协调员将确保适当的样本
收购和贩运。赠款管理员将及时分配资源
促进成功完成拟议的研究。政府的具体目标,
沟通和计划核心是:
1。监控研究进度和未来计划;
我
2。在孢子中和孢子之间促进合作研究;
3。将骨髓瘤孢子整合到DF/HCC结构中;
4。提供必要的资源和财政监督;和
5。促进重大研究发现的快速传播
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
KENNETH C. ANDERSON其他文献
KENNETH C. ANDERSON的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('KENNETH C. ANDERSON', 18)}}的其他基金
Therapeutically Targeting Plasmacytoid Dendritic Cells in Multiple Myeloma
治疗多发性骨髓瘤中的浆细胞样树突状细胞
- 批准号:
9153292 - 财政年份:2016
- 资助金额:
$ 14.51万 - 项目类别:
Therapeutically Targeting Plasmacytoid Dendritic Cells in Multiple Myeloma
治疗多发性骨髓瘤中的浆细胞样树突状细胞
- 批准号:
9518657 - 财政年份:2016
- 资助金额:
$ 14.51万 - 项目类别:
Functional and biologic significance of deacetylase3 inhibition in myeloma
脱乙酰酶 3 抑制在骨髓瘤中的功能和生物学意义
- 批准号:
8757662 - 财政年份:2014
- 资助金额:
$ 14.51万 - 项目类别:
Functional and biologic significance of deacetylase3 inhibition in myeloma
脱乙酰酶 3 抑制在骨髓瘤中的功能和生物学意义
- 批准号:
9320918 - 财政年份:2014
- 资助金额:
$ 14.51万 - 项目类别:
Functional and biologic significance of deacetylase3 inhibition in myeloma
脱乙酰酶 3 抑制在骨髓瘤中的功能和生物学意义
- 批准号:
8916052 - 财政年份:2014
- 资助金额:
$ 14.51万 - 项目类别:
Functional and biologic significance of deacetylase3 inhibition in myeloma
脱乙酰酶 3 抑制在骨髓瘤中的功能和生物学意义
- 批准号:
9127920 - 财政年份:2014
- 资助金额:
$ 14.51万 - 项目类别:
Project 3. Oncogenomics to identify and validate novel targeted therapies in myeloma
项目 3. 用于识别和验证骨髓瘤新型靶向疗法的肿瘤基因组学
- 批准号:
10226194 - 财政年份:2011
- 资助金额:
$ 14.51万 - 项目类别:
Project 3: Defining the biologic role and therapeutic implications of lncRNA in multiple myeloma
项目 3:定义 lncRNA 在多发性骨髓瘤中的生物学作用和治疗意义
- 批准号:
10555733 - 财政年份:2011
- 资助金额:
$ 14.51万 - 项目类别:
Oncogenomics to Identify and Validate Novel Targeted Therapies in Multiple Myelom
肿瘤基因组学识别和验证多发性骨髓瘤的新型靶向疗法
- 批准号:
8066221 - 财政年份:2011
- 资助金额:
$ 14.51万 - 项目类别: